Compassionate Use of Hydroxychloroquine in Clinical Practice for Patients With Mild to Severe COVID-19 in a French University Hospital프랑스 대학 병원의 경증 내지 중증 COVID-19 환자를 위한 임상 실습에서 하이드록시클로로퀸의 자비로운 사용Observational Study Published on 2021-12-062022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 신약개발, 임상, [키워드] addition Admission age Analysis analyzed Arterial hypertension Charlson Comorbidity Index clinical Comorbidity conducted confidence interval confounder confounders contraindication contraindications Controlled trial coronavirus disease Coronavirus disease 2019 COVID-19 death decision defined determine dosage effective French group hazard ratio help Hospitalized Hydroxychloroquine hypertension initial intensive care intensive care unit laboratory-confirmed Laboratory-confirmed COVID-19 medical history Mild National Early Warning Score NEWS2 Nonrandomized studies nonrandomized study not significantly different obesity outcome overall survival Patient patients treated Pneumonia Practice primary analysis primary endpoint Propensity score reduced risk reduction retrospective cohort study risk SARS-CoV-2 score severe COVID-19 severity Sex significantly Standard of care suggested symptom onset the mean the median therapeutic therapeutic agent Treatment treatment of COVID-19 university university hospital was performed Weighting with COVID-19 [DOI] 10.1093/cid/ciaa791 PMC 바로가기 [Article Type] Observational Study
Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled TrialRandomized Controlled Trial Published on 2021-12-062022-10-05 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, [키워드] Adverse adverse event age assigned baseline benefit Complete conducted control arm Controlled coronavirus disease COVID-19 determine diagnosed did not reduce Disease progression early treatment effective eligible event HCQ Hospitalization Hydroxychloroquine intention-to-treat Intervention intervention arm median time Mild Nasopharyngeal swab Open-label Outpatient Patient randomization Randomized Randomized controlled trial randomized, controlled trial receive reduction reported resolution of symptom resolution of symptoms risk SARS-CoV-2 Spain symptom onset the mean therapy Treatment usual care Viral load were assessed with COVID-19 [DOI] 10.1093/cid/ciaa1009 PMC 바로가기 [Article Type] Randomized Controlled Trial
A Machine Learning Approach to Analyze Home Advantage during COVID-19 Pandemic Period with Regards to Margin of Victory and to Different Tournaments in Professional Rugby Union Competitions코로나19 팬데믹 기간 동안 홈 어드밴티지를 분석하기 위한 머신 러닝 접근법Article Published on 2021-12-022022-09-10 Journal: International Journal of Environmental Research an [Category] SARS, 치료기술, [키워드] absence analyzed CHAID club competition complex contribute COVID-19 COVID-19 pandemic decision trees determinants evidenced Final home home advantage Interaction less machine learning margin of victory outcome pandemic Period Perspective positive professional rugby union southern hemisphere Support tendency the mean tournament union unique [DOI] 10.3390/ijerph182312711 PMC 바로가기 [Article Type] Article
The early phase of the COVID-19 epidemic in Lombardy, Italy이탈리아 롬바르디아의 COVID-19 전염병 초기 단계Article Published on 2021-12-012022-09-11 Journal: Epidemics [Category] MERS, SARS, 진단, 치료기술, [키워드] 95% CI analyzed Asia basic reproduction number circulating coronavirus coronavirus disease COVID-19 COVID-19 epidemic CrI Critical case critical cases decrease diagnosed early phase Epidemic Epidemiological investigation Epidemiological investigations Epidemiology estimate explain increase in Infection Intervention Italy laboratory-confirmed lockdown lombardy Lombardy outbreak measure median median age Night Novel coronavirus novel coronavirus disease occurred outbreak Patient Pavia reproduction Reproduction number SARS-CoV-2 Spread suggested sustained the epidemic the mean Transmission Transmission dynamics Variation widespread [DOI] 10.1016/j.epidem.2021.100528 PMC 바로가기 [Article Type] Article
Neurological and cognitive sequelae of Covid-19: a four month follow-upCovid-19의 신경학적 및 인지적 후유증: 4개월 추적Article Published on 2021-12-012022-09-11 Journal: Journal of Neurology [Category] SARS, 치료기술, [키워드] acute COVID-19 affected age cognitive Cognitive impairment Cohort COVID-19 COVID-19 case COVID-19 cases COVID-19 patient COVID-19 patients depression score detectable Diagnosis disorder emotional examined Follow-up Health care Health care worker incidence Infection Mann-Whitney morbidities nervous system neurological Neurological deficit neurological deficits not significantly different past Patient Peripheral nervous system post-acute COVID-19 SARS-COV-2 infection selected significantly higher Stress Support Symptom the mean two patients [DOI] 10.1007/s00415-021-10579-6 PMC 바로가기 [Article Type] Article
Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trialCOVID19로 입원한 환자에 대한 Pentoxifylline 효과: 무작위, 이중 맹검 임상 시험Randomized Controlled Trial Published on 2021-12-012022-09-11 Journal: International immunopharmacology [Category] SARS, 임상, 치료제, [키워드] 1:1 analyzed Anti-inflammatory Anticoagulant antiviral effects assigned baseline changed clinical clinical benefit Clinical characteristics Clinical outcome clinical outcomes clinical trial complications conducted COVID-19 COVID-19 complications demographics dose double-blind Effect Efficacy and safety evaluate Factor glutathione hospital Hospital stay hospitalized patient hospitalized patients Hydroxychloroquine ICU admission IL-6 inclusion criteria individual Inflammation Inflammatory interferon interleukin interleukin-6 intervention group intubation Lopinavir Lopinavir/ritonavir National no significant differences not differ not significant offer oxidative stress Patient patients with COVID-19 Pentoxifylline Placebo placebo group placebo-controlled Primary outcome Randomized randomized clinical trial Randomly recruited regimen Ritonavir safety profile Secondary outcomes Serum level shown significant difference significantly the mean the placebo group two group two groups with COVID-19 [DOI] 10.1016/j.intimp.2021.108227 PMC 바로가기 [Article Type] Randomized Controlled Trial
Differences in pregnancy and perinatal outcomes among symptomatic versus asymptomatic COVID-19-infected pregnant women: a systematic review and meta-analysisResearch Published on 2021-12-012022-10-28 Journal: BMC Pregnancy and Childbirth [Category] COVID-19, SARS, [키워드] 95% confidence interval Adjusted analysis Admission age analyzed article Asian Asymptomatic black body mass index calculated clinical feature clinical presentation Complication complications conducted coronavirus COVID-19 database difference Evidence greater group hypertensive ICU admission identify infected with SARS-CoV-2 information intensive care unit likelihood management mean difference mechanical ventilation Meta-analysis Neonate no significant difference obese objective Odds ratio outcome Pregnancy pregnant pregnant women Preterm birth PROSPERO reported required respiratory disorder Result review risk factor Risk factors SARS-CoV-2 SARS-COV-2 infection significantly lower suggested supplementary material symptomatic systematic review the mean two groups was performed white women [DOI] 10.1186/s12884-021-04250-1 PMC 바로가기 [Article Type] Research
Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19COVID-19 환자의 사이토카인 방출 증후군에 대한 클로로퀸 및 하이드록시클로로퀸의 효과Randomized Controlled Trial Published on 2021-12-012022-09-11 Journal: Clinical medicine & research [Category] SARS, 임상, 치료기술, 치료제, [키워드] Adult patients age blinded Care Chain Reaction Chloroquine conducted coronavirus disease Coronavirus disease 2019 COVID-19 CRS Cytokine release syndrome Department diagnose diagnoses Effect electrochemiluminescence immunoassay Emirate enrolled hospitalized patient Hydroxychloroquine IL-6 interleukin interleukin 6 Medicine Mild mild to moderate mild to moderate symptoms moderate no effect no significant difference onset of symptom Patient patients patients with COVID-19 placebo-controlled polymerase chain polymerase chain reaction randomization randomized study reducing Release Result reverse transcription reverse transcription polymerase chain reaction Roche RT-PCR screened serum sample serum samples significant difference study groups Symptoms the mean the patient three groups Treatment with COVID-19 [DOI] 10.3121/cmr.2021.1659 PMC 바로가기 [Article Type] Randomized Controlled Trial
The Relationship between Routine Blood Parameters and the Prognosis of COVID-19 Patients in the Emergency DepartmentResearch Article Published on 2021-12-012022-10-31 Journal: Emergency Medicine International [Category] COVID-19, [키워드] Admission age Analysis analyzed assist AUC value Blood calculated Combination correlation COVID-19 COVID-19 patient COVID-19 patients CRP cutoff value death Deceased demographic Department diagnosed died Emergency eosinophil ferritin Gender highest hospital Hospital stay Hospitalized identify intensive care laboratory data lowest lymphocyte males mechanical ventilation MLR monocyte Negative predictive value neutrophil NLR pandemic parameter Patient patients physician Platelet Positive predictive value procalcitonin Prognosis relationship routine sensitivity severe COVID-19 severity significant difference specificity statistically survived survivor the disease the mean the patient two group two groups was determined while White blood cell [DOI] 10.1155/2021/7489675 PMC 바로가기 [Article Type] Research Article
Early Fall in C-Reactive Protein (CRP) Level Predicts Response to Tocilizumab in Rapidly Progressing COVID-19: Experience in a Single-Arm Pakistani CenterInternal Medicine Published on 2021-11-302022-10-31 Journal: Cureus [Category] COVID-19, [키워드] 48 hour A significant reduction Adequate age all-cause mortality baseline being category center Clinical data Clinical improvement confirmed COVID-19 case coronavirus disease COVID-19 COVID-19 disease COVID-19 treatment CRP CRP levels demonstrated disease dose Efficacy experience female ferritin level healthcare hospital identify in-hospital mortality inflammatory biomarkers intravenous tocilizumab Level magnitude majority objective outcome Oxygen requirement Oxygenation parameter Patient patients predict Primary outcome Protein receiving response Result secondary outcome Seven significantly increased survival outcome covid-19 the mean the patient Tocilizumab tocilizumab administration Treatment were recorded [DOI] 10.7759/cureus.20031 PMC 바로가기 [Article Type] Internal Medicine